Autosomal recessive primary microcephaly (MCPH) is characterized by reduced head circumference, reduction in the size of the cerebral cortex with otherwise grossly normal brain structure and variable intellectual disability. MCPH is caused by mutations of 11 different genes which code for proteins implicated in cell division and cell cycle regulation. We studied a consanguineous eight-generation family from Pakistan with ten microcephalic children using homozygosity mapping and found a new MCPH locus at HSA 7q21.11-q21.3. Sanger sequencing of the most relevant candidate genes in this region revealed a homozygous single nucleotide substitution c.589G>A in CDK6, which encodes cyclin-dependent kinase 6. The mutation changes a highly conserved alanine at position 197 into threonine (p.Ala197Thr). Post hoc whole-exome sequencing corroborated this mutation's identification as the causal variant. CDK6 is an important protein for the control of the cell cycle and differentiation of various cell types. We show here for the first time that CDK6 associates with the centrosome during mitosis; however, this was not observed in patient fibroblasts. Moreover, the mutant primary fibroblasts exhibited supernumerary centrosomes, disorganized microtubules and mitotic spindles, an increased centrosome nucleus distance, reduced cell proliferation and impaired cell motility and polarity. Upon ectopic expression of the mutant protein and knockdown of CDK6 through shRNA, we noted similar effects. We propose that the identified CDK6 mutation leads to reduced cell proliferation and impairs the correct functioning of the centrosome in microtubule organization and its positioning near the nucleus which are key determinants during neurogenesis.
INTRODUCTION
Primary microcephaly (MCPH [MIM 251200]) is an autosomal recessive neurodevelopmental defect of prenatal brain growth and results in a cerebral cortex which is reduced in size whereas the overall organization of the brain is mostly unaffected, although structural defects in neuronal migration have been reported (1) . Its clinical hallmark is a reduced head size associated with a sloping forehead and variable intellectual disability. In some cases, seizures are also reported. MCPH appears to be evident already prenatally as magnetic resonance imaging (MRI) studies revealed microcephaly with simplified gyration at the 30th and 35th gestational week (2) . The incidence of the disease is 1 in 10 000 in consanguineous populations of northern Pakistan, but less frequent in non-consanguineous populations (1) . Since the identification of the first locus in 1998 (MIM 251200) and the first gene, MCPH1 (MIM 607117), coding for microcephalin, in 2002 (3, 4) , ten additional disease loci and their molecular genetic causes have been described to date. The most recent one is the identification of PHC1 as the novel candidate gene of primary microcephaly in a consanguineous family from Saudi Arabia (5) . At the MCPH2 locus (MIM 604317), mutations of WDR62 (MIM 613583) were reported to cause the disease (6) (7) (8) ; MCPH3 (MIM 604804) is caused by mutations of CDK5RAP2 (MIM 608201) (9,10); MCPH4 (MIM 604321) by mutated CASC5 (MIM 609173) (11, 12) ; MCPH5 (MIM 608716) by mutated ASPM (MIM 605481) (13, 14) ; MCPH6 (MIM 608393) by mutated CENPJ (MIM 609279) (10, 15) ; MCPH7 (MIM 612703) by mutated STIL (MIM 181590) (16) ; MCPH8 (MIM 614673) by mutated CEP135 (MIM 611423) (17) ; MCPH9 (MIM 614852) by mutated CEP152 (MIM 613529) (18) ; and MCPH10 (MIM 615095) by mutated ZNF335 (MIM 610827) (19) . Three patients of a consanguineous Turkish family were diagnosed clinically with a new form of MCPH sharing a homozygous linkage region of 15.8 Mb at HSA 10q11.23-21.3 which is distinct from all known MCPH loci, but the underlying genetic defect could not yet be identified (20) .
All MCPH-associated proteins are ubiquitously expressed and most of them associate with the centrosome at least during part of the cell cycle. Some MCPH-associated proteins are solely localized at the centrosome; others have a nuclear or cytoplasmic localization in interphase and a centrosomal localization only in mitotic cells (7, 8, 17, 18, 21, 22) . Among MCPH-associated proteins, ASPM, WDR62, and STIL have distinct spindle pole localization (7) . The centrosomal localization of the MCPH-associated proteins, particularly during the cell cycle, supports the role of the centrosome in the etiology of primary microcephaly.
The cerebral cortex is established by cell proliferation, migration and differentiation. The type and number of cell divisions of neural progenitor cells in the developing brain determine the number of neurons and ultimately brain size. The principal types of divisions are symmetric, which increase the neural progenitor cell progeny, and asymmetric, which maintain the neural progenitor cell pool and produce the neurogenic progeny (23) . The reduced cerebral cortex volume in primary microcephaly is suggested to result from the imbalance between the symmetric and asymmetric cell division of neural progenitors in the proliferative layer of the developing cortex. Nearly all MCPHassociated genes appear to affect neural progenitor cell number by involving the centrosome (21, 22, 24) . Strong support for this hypothesis was provided by Mcph1-deficient mice in which premature switching of neuroprogenitors from symmetric to asymmetric division was observed. Mcph1 deficiency abrogated recruitment of checkpoint kinase 1 (Chk1) to centrosomes causing premature cyclin-dependent kinase 1 (Cdk1) activation. This resulted in early mitotic entry uncoupling mitosis and the centrosome cycle (25) .
Here, we describe the identification of a new MCPH locus on chromosome 7 at cytoband 7q21.11 -q21.3. As the underlying genetic defect we identified a missense mutation (c.589G.A) in CDK6, the gene coding for the cyclin-dependent kinase 6, replacing a highly conserved alanine residue by threonine (p.Ala197Thr) in the 326 amino acids long polypeptide. CDK6, together with CDK4 and cyclin-D, acts in concert with CDK2 and cyclin-E to regulate the G1 phase and the G1/S transition of the cell cycle. Active CDK4 and CDK6 phosphorylate the retinoblastoma tumor suppressor protein (pRb) allowing cells to enter S-Phase, whereas the INK4 family of inhibitors prevents CDK4/ 6 activity (26) . Cdk6-null mice are viable, develop normally, display normal organogenesis and cell proliferation in most tissues, however, hematopoiesis is impaired (27) .
RESULTS

Patient description
We investigated an eight-generation family (MCP4) from a remote area in South Punjab, Pakistan, affected with MCPH in 10 children of the sixth to eighth generation (Fig. 1A) . Each affected child presented with a sloping forehead and mild intellectual disability (Fig. 1B) . They all had understandable speech and appropriate social behavior. They would dress independently and showed good self-caring skills. We did not observe any sign of self-injurious behavior. There is no history of epileptic seizures. Affected individuals had head circumferences between 24SD and 26SD when compared with the average population of the same age and sex. Apart from that, the patients were healthy and did not show any other neurological deficits. Height was normal in all patients and no defects in the vision were observed. Parents were healthy with normal head circumferences. Standard 1.5 T MRI scans of the affected individuals VI-1 and VII-3 were evaluated by two experts independently and both diagnosed microcephaly with a simplified gyral pattern, but without any gross structural abnormalities.
Identification of the MCPH12 locus
Initially, we excluded all known MCPH loci in the MCP4 family, using STR markers to demonstrate heterozygosity in the relevant genomic regions. We then performed a genome-wide linkage analysis using 250 K SNP arrays from Affymetrix. Based on the analysis of seven affected and two unaffected sibs together with their parents, i.e. in total 11 genotyped individuals, we observed a single peak with a maximum multipoint LOD score of 10.47 on chromosome 7 (Fig. 1C) . The underlying homozygous region, shared between all affected individuals included in the analysis, comprised about 8 cM on the long arm of chromosome 7 at cytoband 7q21.11 -q21.3 ( Fig. 2A ; Supplementary Material, Fig. S1A ). The critical interval of the new locus, which we designated as MCPH12, is defined by the two SNP markers rs17159934 at position 84 908 672 bp and rs42511 at position 92 662 815 bp spanning a region of 7.75 Mb according to the NCBI human genome build 36.3.
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Human Molecular Genetics, 2013, Vol. (Fig. 2C ). This position is highly conserved in vertebrates but it is not conserved among paralogs coding for different CDKs; only CDK4 and CDK6 share the alanine residue at this position (Supplementary Material, Fig. S2 ).
Whole-exome sequencing corroborates CDK6 as MCPH-associated gene
In an attempt to identify a second independent mutation of CDK6, we sequenced CDK6 in patients from eight other families affected with MCPH from Pakistan in which all known MCPHassociated genes were previously excluded. No CDK6 mutation was found in any of these families. Therefore, we decided to perform whole-exome sequencing of one affected child 
Subcellular localization of CDK6
In previous studies, CDK6 was identified in various cell types where it exhibited cytoplasmic and nuclear localization (29, 30) . CDK6 protein was found throughout mouse astrocytes, including the long projections extending from the cell body and within bulbs that protrude from these projections (29) . In a more recent analysis employing monoclonal and polyclonal antibodies, the majority of both endogenous and overexpressed Cdk6 resided in the cytoplasm of mouse astrocytes and NIH3T3 cells with enrichment in the edges and in cytoplasmic extensions where it partially colocalized with actin (31) . CDK6 was also observed in the ruffling edge of human fibroblasts indicating a role in cell spreading (32) . All these studies focused on the localization of CDK6 in non-dividing cells. We followed its subcellular distribution throughout the cell cycle by staining HaCaT cells using two different monoclonal CDK6-specific antibodies (Supplementary Material, Fig. S3A and B). Both antibodies revealed the presence of CDK6 in the cytoplasm and in nuclei of non-dividing cells. In dividing cells, cytoplasmic staining was reduced and a dot-like staining remained near the cell periphery. In addition, a specific dot-like staining located opposite to each other on both sides of the metaphase plate appeared (Supplementary Material, Fig. S3B ). By costaining with the centrosomal marker pericentrin, we found that CDK6 surrounded pericentrin. Furthermore, CDK6 accumulated at the centrosome throughout the mitotic cycle (Supplementary Material, Fig. S4 ). This distribution of CDK6 resembles the one of WDR62 during mitosis (7) . CDK6 was present in the cytosol and in the nucleus in interphase cells and at the centrosome during mitosis from prophase to telophase (Fig. 3 ).
Abnormalities of CDK6 patient primary fibroblasts
No alterations in the amount of CDK6 protein were detected in the patient when compared with control (Supplementary Material, Fig. S5A ). We also tested whether the c.589G.A mutation has an effect on splicing resulting in exon skipping. Using two sets of primers (Supplementary Material, Table S1 ) spanning the exon 4d-6 and 4 -7 in order to amplify complementary DNA (cDNA) from two different blood samples and fibroblasts we did not get any hint for exon skipping in patients and their parents (Supplementary Material, Fig. S5B ).
The examination of the CDK6 localization in mutant primary fibroblasts revealed that in interphase cells, the staining was as in control fibroblasts. However, during mitosis, we observed changes in comparison to the control as CDK6 was not found on centrosomes. Remarkably, the mitotic spindles of these cells were disorganized (Fig. 4) .
Next, we analyzed the centrosome and the microtubule network in control and patient fibroblasts. Primary fibroblasts from healthy donors have a single centrosome and an organized microtubule network during interphase, and two centrosomes and a well-organized spindle apparatus with spindle and astral microtubules throughout mitosis (Fig. 3) . Analysis of the patient fibroblasts (CDK6 proband VIII-1) revealed remarkable abnormalities. When we focused on the microtubule network and on centrosomes in interphase cells, we observed that the microtubules did not form as regular a network as in control fibroblasts. During mitosis we also found abnormal spindle alignment (Fig. 4) . Statistical analysis revealed 48% of dividing cells with disorganized spindle microtubules (Supplementary Material, Fig. S6A ). Furthermore, the nuclei of patient fibroblasts as detected by 4
′ , 6-diamidino-2 ′ -phenylindole (DAPI) staining were misshapen and exhibited often a lobulated morphology or appeared aggregated (Fig. 5A ). About 12% of all patient cells had misshapen nuclei. This number was only 2% for control fibroblasts ( Fig. 5C ; Supplementary Material, Table S2 ). Some of the cells with misshapen nuclei carried only one centrosome as revealed by pericentrin staining, others contained two centrosomes, some were with supernumerary centrosomes and often the centrosomes appeared aggregated (Fig. 5A, inset ). Centrosomes detected with pericentrin-specific antibodies were frequently detached from nuclei and exhibited a significantly increased distance. In mutant primary fibroblasts, the mean centrosome-nucleus distance amounted to 5.1646 mm when compared with 3.4514 mm in controls ( Fig. 5B ; Supplementary Material, Table S2 ).
Supernumerary centrosomes persisted during mitosis. We could observe several centrosomes during prophase, where two centrosomes stayed near the nucleus whereas the third one was at some distance ( Fig. 5E ). We did not observe any significant proportion of cells with multipolar spindles which lead to polyploidy. Cell proliferation was reduced when compared with control cells. When we determined the number of dividing CDK6 mutant and control primary fibroblasts that had been synchronized at G0/G1, we found 3% of control cells in different stages of the cell cycle, whereas this number was significantly reduced in the mutant with only 0.3% of dividing cells confirming an altered proliferation rate ( Fig. 5D ; Supplementary Material, Table S2 ). In addition, the patient primary fibroblasts showed a reduced growth rate when compared with the control (Supplementary Material, Fig. S6B ). Next, we tried to confirm whether the growth impairment of patient fibroblasts is due to excessive apoptosis or to pRb (retinoblastoma-associated protein) hypophosphorylation. Fluorescence-activated cell sorting (FACS) analysis of patient and control primary fibroblasts detected a higher percentage of late-apoptotic patient cells, while the difference of pre-apoptotic cells was not significant (Supplementary Material, Fig. S6C -E). These apoptotic cells might cause the misshapen nuclei observed in patient fibroblasts. Analysis of pRb phosphorylation in primary fibroblasts synchronized at G0/G1 showed a significant difference as data from two independent experiments revealed hypophosphorylation of pRb in patient cells Human Molecular Genetics, 2013, Vol. 22, No. 25 5203 Fig. S6F ). Therefore, the growth impairment appears to be linked both to increased apoptosis and to pRb hypophosphorylation which prevents cell proliferation. We conclude that the presence of mutated CDK6 protein causes centrosome dysfunction and impaired cell proliferation.
CDK6 knockdown causes microtubule and centrosome aberrations and defects in cell division cycle
To obtain independent support for a role of CDK6 at the centrosome and in cell proliferation, we carried out knockdown experiments in HaCaT cells using the shRNA technique. In control HaCaT cells, the microtubule network as well as mitotic spindles were well organized and the correct number of centrosomes was present (Fig. 6A) . In CDK6 knockdown cells, supernumerary centrosomes were noticed during interphase and different cell division phases. The supernumerary centrosomes in dividing cells occasionally led to the formation of multipolar spindles (Fig. 6B) . In CDK6-knockdown cells, we also noticed disorganized microtubules in interphase cells (Fig. 6C ) and disorganized spindle apparatus in mitosis ( Fig. 6D and E) . In analogy to the patient cells, knockdown of CDK6 led to the appearance of dysmorphic nuclei (Fig. 6F ). Statistical analysis showed misshapen nuclei in 21% of the knockdown cells when compared with 10% in control cells ( Fig. 6G ; Supplementary Material, Table S2 ). When we assessed proliferation we found that the percentage of dividing cells was 4.45% in knockdown cells versus 15.3% in the control ( Fig. 6H ; Supplementary Material, Table S2 ). The efficiency of the knockdown was confirmed by western blot analysis (Fig. 6I) . Centrosomal localization of CDK6 in wild-type primary fibroblasts. Immunofluorescence images of control primary fibroblasts stained with antibodies against CDK6 (red), pericentrin (turquoise), a-tubulin (green) and DAPI (blue). All mitotic phases from prophase to telophase confirm the centrosomal localization of CDK6 and well-organized microtubules and spindles. Scale bar, 5 mm or as indicated.
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Taken together, CDK6 knockdown by shRNA led to microtubule disorganization, spindle misalignment and nuclear shape changes, and had an impact on cell proliferation consistent with the data obtained from the analysis of patient primary fibroblasts. Hence, we conclude that CDK6 deficiency affects microtubule organization, mitotic spindle alignment and has a role in the centrosome cycle.
CDK6 patient primary fibroblasts and knockdown show impaired cell motility and polarity
To unravel the role of CDK6 in cell migration and polarity, we performed cell motility and polarity assays using a gap closure setup. For determining cell motility of CDK6 patient primary fibroblasts, cells from three different experiments (200 cells per experiment) were analyzed. We observed a significant difference in gap closure of control and mutant primary fibroblasts (Supplementary Material, Fig. S7A and B, left panels). Analysis of the data revealed that control fibroblasts moved significantly faster (0.63 + 0.01 mm/min) to close the gap when compared with the patient fibroblasts which moved with a speed of 0.43 + 0.03 mm/ min (Supplementary Material, Fig. S7C ). The alteration in the motility of patient fibroblasts was mimicked by HaCaT cells transfected with a CDK6 knockdown plasmid (Supplementary Material, Fig. S7A and B, right panels). The statistical analysis showed a difference in the velocity of 0.2 mm/min between knockdown and control cells (Supplementary Material, Fig. S7D ). The knockdown was confirmed in immunoblots (Supplementary Material, Fig. S7E ).
For cells to migrate toward a gap, they have to properly orient and polarize. To examine this behavior in detail, we submitted the monolayers at various time points after start of the experiment to an immunofluorescence analysis and stained for pericentrin and a-tubulin. The centrosome is a well-known structure that reorients when the cells polarize. In these experiments, we found that CDK6 patient primary fibroblasts were less efficient in repo Ectopic expression of wild-type and mutant CDK6 causes defects in microtubule organization and centrosome numbers
To identify the effect of overexpressed wild-type and mutant CDK6 protein, we transfected COS7 cells which express endogenous CDK6 with plasmids, allowing the expression of GFP-tagged wild-type and mutant CDK6. During interphase, wild-type GFP-CDK6 was present in the nucleus revealing a dotted staining. The observed dots were variable in size and number (Fig. 7A) . Mutant GFP-tagged CDK6 behaved differently. In interphase cells, a diffuse distribution was identified in the nucleus. Cytoplasmic localization was not seen (Fig. 7B) . As we did not detect even a single dividing cell, we could not study the redistribution of CDK6 to the centrosome during mitosis.
We then analyzed microtubules and centrosomes. COS7 cells overexpressing wild-type CDK6 had a single centrosome and a well-organized microtubule network, in contrast, overexpression of the mutant protein caused a disorganization of the microtubule network ( Fig. 7A and B) . Detection of supernumerary and fragmented centrosomes was another prominent feature of cells expressing the mutant protein. These supernumerary centrosomes were found in groups. The groups were situated apart from each other and the number and shapes of the centrosomes in these groups were variable, and some centrosomes clumped together (Fig. 7B) . The centrosome abnormalities thus resembled the one in CDK6 patient primary fibroblasts and in the CDK6 knockdown, and the microtubule disorganization was reminiscent of the one observed in CDK6 knockdown cells.
Expression profile of CDK6 in mammalian cerebral cortex development
In MCPH, neurogenesis during development is presumably affected. To examine Cdk6 during mammalian cerebral cortical neurogenesis, immunofluorescence studies were performed with mouse sections obtained from embryonal stages E11.5 and E15.5. These are the stages when neurons are produced to establish the cerebral cortex (33, 34) . At both stages we observed staining for Cdk6 in the developing neuroepithelium of the cerebral cortex (Fig. 8) . At E11.5, we detected Cdk6 in a specialized type of cells which may be intermediate or 'basal' progenitors (Fig. 8A, arrow) (34) , while at E15.5 it was present in all the major sites of the developing neuroepithelium. At E15.5, Cdk6 staining was prominent at the apical ventricular surface where the apical precursors reside showing a cytosolic localization (Fig. 8B) . Cdk6 was also seen in the basal progenitor cells of both embryonal stages E11.5 and E15.5, which eventually 
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Human produce neurons by symmetric division in the basal region of the ventricular zone (VZ) and in the subventricular zone (SVZ) (35, 36) . Higher magnification revealed that CDK6 localized to the cytosol of the neurons with prominent staining around either side of the nucleus (Fig. 8C ).
DISCUSSION
The identification of missense mutation p.Ala197Thr in CDK6 as the causative variant for the observed phenotype in a large Pakistani family with MCPH prompted us to investigate the role of the corresponding protein in the cell cycle. It was known that the cyclin-dependent kinase CDK6 together with CDK4 and cyclin-D act in concert with CDK2 and cyclin-E to regulate the G1 phase and the G1/S transition of the cell cycle. Active CDK4/6 phosphorylates pRb allowing cells to enter the S-phase, whereas the INK4 family (p15INK4b, p16INK4a, p18INK4c and p19INK4d) of inhibitors prevents CDK4/6 activity (37) . In quiescent cells, the binding of INK4 proteins to CDK4 and CDK6 shifted the Cip/Kip proteins (another family of cyclin-dependent kinase inhibitors) from CDK4/CDK6 to cyclin-E-CDK2 and cyclin-A-CDK2 complexes resulting in the inhibition of all other CDKs (38) . The direct consequences of the mutation CDK6:p.Ala197Thr are currently unclear as the affected region is not directly implicated in cyclin or INK binding, nor is the ATP-binding site or the catalytic center directly affected but we have found a tendency of decreased phosphorylation of pRb in patient fibroblasts when compared with the control. However, the mutation occurs in a loop the structure of which is variable if different CDK structures are compared (data not shown). This mutation probably causes the abnormal mitotic morphology by acting as a loss-of-function mutation because we observed similar cellular defects in patient primary fibroblasts, in cells synthesizing the mutant version of the protein and in CDK6-knockdown cells. Importantly, there is an impact of this mutation on the cellular localization as the patient primary fibroblasts failed to recruit CDK6 to the centrosome during mitosis. A difference in the CDK6 localization pattern was also observed in cells producing wild-type and mutant protein, where a spot-like staining was observed in wildtype cells and a diffused nuclear staining in cells producing the mutant protein. These data suggest that p.Ala197Thr can abrogate the accumulation of CDK6 on the centrosome which might be the cause of MCPH12 microcephaly.
Ectopic expression of CDK6 was reported to result in a higher percentage of S phase cells and a shorter G1 interval. A CDK6 mutant (p.Arg31Cys) reduced the proliferative efficiency in U2OS cells, although it was capable of in vitro pRb phosphorylation. Moreover, this mutation disturbed the INK4 CDK6 interaction and prevented CDK6 accumulation in the nucleus (39) . Our data of a reduced proliferation capacity in CDK6 patient primary fibroblast and in knockdown cells are in agreement with these observations. CDK6 not only functions in cell cycle progression, but also plays a role in the differentiation of a variety of cell types (40) . It has been described as a cytoplasmic as well as a nuclear protein (35) . Surprisingly, its loss does not grossly interfere with viability and normal physiology of Cdk6-null mice with the exception of hematopoiesis (27) .
The results from patient fibroblasts, CDK6 protein reduction in HaCaT cells by knockdown and expression of the CDK6 mutant version in COS7 cells all show similar defects in the microtubule network, namely a disorganized network in interphase cells and spindle misalignment in mitosis leading to defective bipolar spindles. Mouse neuroprogenitor cells lacking Mcph1 and NIH3T3 cells in which Mcph1 levels were reduced by a knockdown showed similar aberrations (25) . Our data of surplus centrosomes observed in patient, knockdown and COS7 cells expressing mutant CDK6 is also in line with the previously reported data of supernumerary centrosomes reported in patient cells carrying mutations in other MCPH-associated genes (MCPH1, CEP152, CEP135) and in chicken and mouse cells, in which MCPH-associated genes (Mcph1, Cdk5rap2) were mutated by ionizing radiation, knocked down or expressed as mutant alleles (17, 25, (41) (42) (43) (44) (45) .
The described association of CDK6 with centrosomes in normal cells during division and the centrosomal abnormalities 
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observed in patient cells and cells lacking CDK6 point toward a novel role of CDK6 in centrosome function. The presence of abnormal centrosome number (multiple centrosomes in the form of aggregation) noticed in CDK6 patient primary fibroblasts might suggest a failure in centriole biogenesis and attribute a role to CDK6 in the centrosome cycle. Centrosome duplication is intimately linked to the cell cycle and for cyclin-dependent kinases CDK1 and CDK2 such an involvement has already been reported (24, (46) (47) (48) . In Caenorhabditis elegans, the cyclin-E-Cdk2 active complex which is an important component for the transition of G1 to S phase of the cell cycle is also required for the recruitment of spindle-defective protein-2 (SPD-2) to the mother centriole. SPD-2 has a role in centriole duplication and centrosome maturation. It recruits ZIG-1 which in turns recruits a complex of SAS-5 and SAS-6 proteins necessary for inner centriole tube formation (46, 49) . Further, CDK2 is required for centriole disengagement, and active cyclin-B1-Cdk1 accumulates on centrosomes and is involved in centrosome separation and mitotic spindle assembly (48, 50, 51) . Our data of impaired cell motility and polarity observed in CDK6 patient fibroblasts and knockdown cells reveal an additional and novel role of CDK6 in cell migration and cell polarity. Perturbation in the migration of neurons and glia cells have also been suggested in patients carrying mutations in MCPH1 and WDR62 (1, 8) .
In addition to altered centriole biogenesis, the centrosome abnormalities of CDK6 patient fibroblasts could also result from perturbed centrosome duplication through the RB/E2F pathway which regulates centrosome duplication (52) and is phosphorylated by CDK6-Cyclin-D. Cyclin-D1 and D2 are expressed in the neural progenitor cells of the VZ and SVZ, respectively. Mice lacking cyclin-D2 show reduced proliferation and enhanced cell cycle exit in embryonic cortical progenitors and are microcephalic (53, 54) . A thin cortex and a great reduction in volume were observed in superficial and deeper cortical layers. Cyclin-D2 is also important for the transition of radial glial cells to intermediate progenitor cells (IPCs) and for expansion of the IPC number (54) . Moreover, a functional loss of cyclin-D2 but not D1 in mice during adult neurogenesis abrogates the proliferation capacity of neuronal precursors in the adult brain (55) . CDK6 activity has been observed at the mid G1 phase of the cell cycle and is responsible for G1 progression and G1 to S phase transition. These are the stages where centrosomes and subsequently genomic DNA are duplicated and mutation in CDK6 might cause disturbance in these processes.
During the initial stages of cortical development, selfrenewing symmetric cell division of neural progenitor cells is essential to generate sufficient numbers of cells, which serve as a pool for ongoing neurogenesis (56) . In the neuroepithelium, premature and early differentiated neurons are present. Proliferation takes place in the VZ and SVZ. Upon asymmetric cell division, neural progenitor cells give rise to two different cells which have different cellular fates. One type of cells enters neurogenesis and the other retains the proliferative capacity. The cells present in the VZ are mitotic and premature neuronal cells, which upon differentiation give rise to postmitotic differentiated neurons. Detection of CDK6 at E11.5 and E15.5 in mouse embryonic development shows that Cdk6 is expressed in the neuroepithelium of the developing cortex during neurogenesis. This localization is reminiscent of that of WDR62, a Human
spindle pole protein expressed in neuronal precursor cells undergoing mitosis in mammalian embryonic neuroepithelium. Mutations in this protein decrease the number of neuronal precursor cells leading to microcephaly (7, 8) . The MCPH-associated proteins WDR62, ASPM and STIL are located at the spindle pole, which controls the position of the central spindle and regulates proper cytokinesis (7). We localized CDK6 at the centrosome as well. Our findings are supported by data from knockout mice, which show that Cdk6 is involved in the proliferation of neural precursors of the subgranular zone (SGZ) and SVZ. Also, the protein is synthesized in the neural precursors of SGZ and SVZ. It was further found that the neural precursors of the dentate gyrus and SVZ in Cdk6-knockout mice exit the cell cycle prematurely and exhibit a lengthened G1 phase of the cell cycle due to pRb hypophosphorylation. This process leads to the reduction of the neural precursor pool and ultimately fewer neurons. In the light of these data, the authors proposed a crucial role for Cdk6 in maintaining the pool of neuronally committed precursors and fine-tuning neuronal production (57) . CDK6 also plays an important role in early stages of neuronal apoptosis by the cyclin-D-CDK4/6-Rb/p107/p130 pathway, where the activity of cyclin-D-CDK4/6 is upregulated and E2F transcription factor down regulated (58) .
In summary, we have identified the underlying genetic defect for a novel MCPH locus on the long arm of chromosome 7 (MCPH12). The mutated gene is CDK6 for which we propose a novel role at the centrosome during the cell cycle phases. The disorganized microtubules and spindles, misshapen nuclei, supernumerary centrosomes observed in patient and knockdown cells as well as cells expressing the mutant allele of CDK6, depict this novel role, while the reduced proliferation observed in patient and knockdown cells underpins its known role in cell cycle control. Our study has brought new insight into the role of cyclin-dependent kinases. In addition, the centrosomal association of CDK6 corroborates the role of centrosomes in the etiology of MCPH. We propose that mutations in CDK6 affect the proliferation of apical neuronal precursor cells and/ or create an imbalance of symmetric and asymmetric cell division resulting in depletion of the progenitor pool which may be the cause of reduced neuron production and finally primary microcephaly.
MATERIALS AND METHODS
Subjects
Ethical approval for this study was obtained from the ethics review board at the National Institute for Biotechnology and Genetic Engineering in Faisalabad according to the Declaration of Helsinki. A field sampling trip was organized into a remote area of South Punjab in Pakistan. After informed consent of the parents was obtained, pedigree information of family MCP4 was documented and clinical data and blood samples were collected. This family has 24 living family members, 10 of them having MCPH. Blood samples were obtained from 11 members including 7 affected ones (Fig. 1A) . 384 healthy unrelated individuals were recruited as controls from the same area.
SNP array mapping and linkage analysis
Genomic DNA was isolated from blood samples using a standard phenol-chloroform method. Exclusion mapping was performed using STR markers representing all known MCPH loci. Thereafter a genome-wide screen for regions of homozygosity was performed using the Affymetrix Human Mapping 250 K SNP GeneChip Sty Array according to the manufacturer's recommendations (Affymetrix, Santa Clara, CA). Data handling, evaluation, and statistical analysis were performed as described previously (17) . In brief; we selected a subset of 126 000 SNPs with a minor allelic frequency of 0.15 or higher for linkage analysis. Mendelian errors were detected by the program PedCheck. LOD scores were calculated with Allegro.
Candidate gene sequencing
We retrieved all genes within the critical linkage interval on chromosome 7 from the NCBI gene database (http://www. ncbi.nlm.nih.gov). The genes were then prioritized using Endeavour (http://homes.esat.kuleuven.be/~bioiuser/endeavour/ tool/endeavourweb.php) and GeneWanderer (http://compbio. charite.de/genewanderer/GeneWanderer). Structures of highly ranked genes were verified using ENSEMBL (http://www. ensembl.org) and UCSC (http://genome.ucsc.edu) genome databases. Of the selected candidate genes, we sequenced all exons and exon -intron boundaries in two affected and one normal sibling as well as one parent (CDK6 primers are listed in Supplementary Material, Table S3 ). PCR products were sequenced on an ABI3730xl automated DNA sequencer using the BigDye Terminator v1.1 cycle sequencing kit. Sequences were analyzed using the DNA Star (Lasergene) and Mutation Surveyor (Softgenetics) software packages. For segregation analysis of the detected CDK6 mutation, exon 5 was sequenced in all available DNA samples of the MCP4 family. Moreover, 384 healthy control individuals from Pakistan and 380 healthy German controls were tested by direct Sanger sequencing for that particular mutation.
Whole-exome sequencing
One microgram of DNA from individual VII-5 was fragmented by ultrasonic treatment (Covaris, Inc., Woburn, MA 01801, USA). The fragments were end-repaired and adapters ligated. After size selection, the libraries were subjected to the enrichment process. We chose the SeqCap EZ Human Exome Library v2.0 kit from NimbleGen (Roche NimbleGen Inc., Madison, WI 53719, USA) and ran the sample on an Illumina HiSeq TM 2000 sequencing instrument. About 10 Gb of sequence were produced for this sample by loading it individually on one lane of a flow cell and generating paired-end reads of 2 × 100 bp. This resulted in a very high coverage, i.e. .30 times for nearly 92% of the target sequences which comprised about 44 Mb. Primary data were filtered according to the signal purity by the Illumina Realtime Analysis (RTA) software v1.8. Subsequently, the reads were mapped to the Human Genome reference build version hg19 using the ELANDv2 alignment algorithm on a multi-node compute cluster. Using CASAVA v1.8, PCR duplicates were filtered out and the output was converted into BAM format. Variant calling was performed using 
Cell line establishment from patient biopsy
A biopsy sample was taken from one affected individual (VIII-1) and transported in DMEM with amphotericin B and gentamycin. Tissue samples were cleaned with an antiseptic agent (Betaisodonna, Mundipharma) and incubated overnight with Dispase II (1.5 U/ml, Roche) diluted in phosphate buffered saline (PBS) at 48C to separate intact epidermis from dermis. The dermis was incubated in DMEM media at 378C. After 1 week, fibroblasts were seen. The pool of primary fibroblasts was increased by further culturing.
Fibroblast synchronization
CDK6 patient and control fibroblasts (passage 4) were synchronized at G0/G1 by serum starvation. The medium was exchanged by two washes with PBS and then DMEM without FBS was added. After 48 h, the medium was changed with DMEM containing 15% FBS. The cells were processed for immunofluorescence after 24, 26, 28 and 30 h. To analyze the phosphorylation of pRb, synchronized cells were harvested for immunoblotting at 0, 4, 8, 12, 24, 48 , and 72 h after release from the G1 block.
Determination of growth
Patient and control primary fibroblasts (1 × 10 5 ) were cultured in six different plates as described above. After trypsinization, the cells were counted at consecutive days and the data was recorded for final results.
Analysis of apoptosis
Primary patient fibroblasts, Passages 3 and 4, and control fibroblasts, Passages 4 and 6, were used for the analysis. After trypsinization, 1 × 10 6 cells in HEPES buffer (PAN Biotech) were stored on ice. After incubation with APC Annexin V and 7-AAD (Biolegend, San Diego, CA, USA), for 15 min at room temperature, the apoptotic cells were analyzed immediately by using the BD FACSAira III cell sorter (BD Bioscience USA).
Construction of vectors to knockdown CDK6 by shRNA CDK6 gene silencing was performed using the shRNA technique. The Hairpin Protocol V2.1 was used to design the primers (http:// hannonlab.cshl.edu/protocols/BseRI-BamHI_Strategy.pdf). Two different sets of primers were designed using 31 nucleotides from exons 4 (5 ′ -GATCTAAAACCACAGAACATTCTGGTGACC A-3 ′ ) and 7 (5 ′ -TGAGAAGTTTGTAACAGATATCGATGAA CTA-3 ′ ) of CDK6. For control, the sequence of the primer derived from exon 7 was randomized to get the sequence 5
′ -TTAAAA GAGCTAGTTTAACTAATGGGAACTG-3 ′ by using DNA Protein Sequence Randomizer (http://www.cellbiol.com/scripts/ randomizer/sequence_randomizer.html) (for primer sequences see Supplementary Material, Table S4 ). The annealed oligonucleotides were ligated into pSHAG-1 using BseRI and BamHI (60). The plasmids were used for transfection of HaCaT cells by using Amaxa Cell line Nucleofector (R) Kit V (LONZA). Transfection was carried out twice with a three-day interval. A high knockdown efficiency was achieved with the constructs derived from exon 7.
Construction of eukaryotic expression vectors
Gateway
w Technology (Invitrogen) was used to engineer genes coding for N-terminally tagged GFP wild-type human CDK6 as well as mutated CDK6. RNA from control and patient primary fibroblasts was isolated using the RNeasy mini kit (Qiagen). cDNA was synthesized using total RNA with SuperScript III reverse transcriptase (Invitrogen). The CDK6 transcript (NM_001145306.1) from wild-type and mutant cDNA was amplified with forward primer 5 ′ -CACCATGGAGAAGGACGGCC TG-3 ′ and reverse primer 5 ′ -GCAGAGCCTGTCCAGAAGAC -3
′ . The PCR products were first cloned into the entry vector pENTR TM /TEV/DTOPO w by using the pENTR TM Directional TOPO w Cloning Kit (Invitrogen) to get the entry clones. Expression clones of wild-type and mutant CDK6 obtained by performing an LR recombination reaction (Gateway w LR Clonase TM II Enzyme Mix, Invitrogen) between the entry clone and a Gateway w destination vector pcDNA-DEST53 (Invitrogen) which has an N-terminal cycle 3 GFP tag. The correct orientation of the DNA fragments was confirmed by Sanger sequencing.
Protein expression in eukaryotic cells
For ectopic expression of wild-type and mutated CDK6, the plasmids were introduced into COS7 cells (at 80% confluency and trypsinized one day before transfection) by electroporation using GENE PULSER II (BIO-RAD). Immunofluorescence and protein extraction were performed 72 h after transfection. Amaxa Cell line Nucleofector (R) kit V (LONZA) was used to transfect HaCaT cells with CDK6-knockdown constructs (3 mg). Transfection was carried out twice with 3 days interval. Immunofluorescence analysis and preparation of protein lysates were done on the third day after the second transfection.
Protein detection by immunoblotting
Cells were scraped into 1X PBS plus protease inhibitor (DTT, Benzamidine and PMSF at 1 mM each). After pelleting, the cells were lysed in lysis buffer [ Germany) . After blocking and incubation with primary antibodies, the membrane was incubated with IgG peroxidaseconjugated secondary antibodies and blots were developed using an enhanced chemiluminescence system. Signal intensities of protein bands detected by specific antibodies were estimated using the Spot Denso algorithm of the AlphaEaseFC TM software (version 4.0.0) (Alpha Innotech, San Leandro, CA, USA).
Immunocytochemistry
Cells were cultured on 12 mm coverslips and fixed with 3% paraformaldehyde. For microtubule staining, cells were incubated in tubulin stabilization buffer for 15 min. Tubulin stabilization buffer (pH 6.8) contains HANK'S Buffer (137 mM NaCl, 5 mM KCl, 1.1 mM Na 2 HPO 4 , 0.4 mM KH 2 PO 4 , 5 mM glucose, 4 mM NaHCO 3 ), 1 mM MES, 2 mM EGTA and 2 mM MgCl 2. Permeabilization was done by 0.5% Triton X-100 in 1X tubulin stabilization buffer for 4 min at room temperature. For g-tubulin detection, the cells were fixed with prechilled absolute methanol for 10 min at 2208C without permeabilization. Subsequently the fixed cells were treated three times with tubulin stabilization buffer. Blocking was done for 15 min with blocking buffer (1X PBG: PBS containing 5% BSA and 0.45% fish gelatine). Primary antibodies were diluted in blocking buffer and incubated overnight at 48C. After incubation with 1X PBS three times for 5 min, secondary antibodies (1:1000 diluted in blocking buffer) were added for one hour at room temperature. After washing three times with 1X PBS, the cells were mounted on glass slides with gelvatol. Images were taken by confocal microscopy (Leica, LSM TCS SP5).
Cell motility and polarity assay CDK6 patient and control primary fibroblasts and HaCaT cells transfected with CDK6 knockdown and control plasmids were cultured as mentioned above. For cell migration assays, microslide chambers and inserts creating a 500 mm cell free gap (ibidi, Martinsried, Germany) were used. Equal amounts of cells were seeded. After 24 h, the inserts were removed and live cell imaging was performed using a Leica DMI 6000 B microscope. Images of the cells were taken every 15 min for 12.5 h. ImageJ software was used to determine single cell velocity from 200 cells per assay. For the polarity assay, the inserts were deposited directly onto 12 mm coverslips to create the gap between the cells. The cells were fixed at different time points (0, 45, 180, and 420 min) and processed for immunofluorescence with pericentrin and tubulin specific antibodies. To measure the polarity of the cells, the centrosomal position toward the gap was measured by a 1208 angle from the center of the nucleus toward the gap. Cells within this angle were considered as oriented.
Immunohistochemistry of paraffin-embedded embryo sections
Wild-type mouse embryos at E11.5 and E15.5 were fixed with 4% paraformaldehyde overnight. Embryos were washed with PBS, stored in 70% ethanol and embedded in paraffin. Paraffinembedded sections (6 mm) were de-paraffinized and heat-mediated antigen retrieval was performed (61) . Sections were blocked with PBG for 2 h at room temperature. After incubating overnight at 48C with primary antibodies diluted in PBG, sections were washed with PBS, and incubated with fluorescent-conjugated secondary antibodies (Invitrogen-Molecular Probes) for 1 h. Nuclei were visualized with DAPI. After three washes with PBS, sections were mounted and imaged with a Leica confocal microscope.
Antibodies
For immunoblotting, a mouse monoclonal CDK6 antibody (Abcam, ab54576) was used (1:500) to detect CDK6 protein in knockdown and control cells. The mouse monoclonal anti-bActin (Sigma, A5316) antibody (1:10 000) was used as a loading control. Anti-mouse IgG peroxidase-conjugated (Sigma, A4416) secondary antibody (1:10 000) was used for detection. For pRb analysis, rabbit polyclonal pRb (cell signaling, 9307) was used, and rat monoclonal anti Y/L1/2 was used as a loading control (62) . An anti-rat IgG peroxidase-conjugated (Sigma, A5795) secondary antibody (1:10 000) was used for detection. . DNA was detected with (DAPI) (Sigma, D9564). For immunohistochemistry, the sections were incubated overnight at 48C with primary mouse-monoclonal CDK6 and chicken anti-nestin (Neuromics, CH23001) antibodies diluted in PBG. Fluorescent-conjugated secondary antibodies (Invitrogen-Molecular Probes) were used for 1 h. Nuclei were visualized with DAPI.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
